by American College of Physicians Credit: Pixabay/CC0 Public DomainA study of more than 250 persons undergoing surgical therapy for Cushing’s disease (CD) or nonfunctioning pituitary adenomas (NFPAs) found that patients who achieved remission of CD were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within three years after remission. The study...
by Pasteur Institute The anti-SIV antibody levels after treatment interruption are associated with the magnitude of antigen stimulation. Kinetics of plasma anti-gp140 SIV IgG (A) and IgA (E) in W4-treated and W24-treated CyMs. Comparison of anti-gp140 SIV IgG (B) and IgA (F) levels between W4- and W24-treated CyMs at baseline, on day 28 p.i.; at 6...
Engineered immune cells, most commonly used to treat cancers, show their power against lupus and other immune disorders. Composite coloured scanning electron micrograph (SEM) of T-cells (small round) and a cervical cancer cell (Hela) T cells (smaller cells) can be engineered to recognize cancer cells — and also other immune cells.Credit: Steve Gschmeissner/Science Photo Library...
Kevin Fernando, MBChB, MScDISCLOSURES October 17, 2023 The prospect of remission of type 2 diabetes (T2D) has captured the hearts and minds of many patients with T2D and healthcare professionals, including myself. Kevin Fernando, MBChB, MSc I have changed my narrative when supporting my patients with T2D. I used to say that T2D is a progressive condition,...
By Adrianna Nine May 31, 2023 Credit: ANIRUDH/Unsplash Multiple myeloma, one of the world’s most common blood disorders, has long been considered incurable. This form of cancer impacts plasma cells, crowding out healthy blood cells and spreading to multiple bone marrow sites throughout the body. Although drugs, radiation, and chemotherapy sometimes reduce patients’ symptoms and...
Could a two-drug combination improve treatment response in late-stage melanoma? Glasshouse Images/Getty Images Researchers tested the efficacy of a drug combination for treating stage IV melanoma. They found that 71% of patients responded to the drug combination, and 50% had complete remission. The drug combination is now entering a larger trial with a more diverse cohort....
Ana Jiménez-Ubieto, M.D., Ph.D., from the Hospital Universitario 12 de Octubre in Madrid, and colleagues examined whether ASCT is an effective option in the pre-rituximab era for patients treated in induction and rescued only with chemotherapy. Two groups were identified: the ETF cohort (87 patients) and the non-ETF cohort (47 patients). The researchers found that five-year progression-free...
